K
Keisuke Tomii
Researcher at Wakayama Medical University
Publications - 252
Citations - 5584
Keisuke Tomii is an academic researcher from Wakayama Medical University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 35, co-authored 220 publications receiving 4306 citations. Previous affiliations of Keisuke Tomii include Nagasaki University.
Papers
More filters
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.
Journal ArticleDOI
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
Riichiroh Maruyama,Yutaka Nishiwaki,Tomohide Tamura,Nobuyuki Yamamoto,Masahiro Tsuboi,Kazuhiko Nakagawa,Tetsu Shinkai,Shunichi Negoro,Fumio Imamura,Kenji Eguchi,Koji Takeda,Akira Inoue,Keisuke Tomii,Masao Harada,Noriyuki Masuda,Haiyi Jiang,Yohji Itoh,Yukito Ichinose,Nagahiro Saijo,Masahiro Fukuoka +19 more
TL;DR: Gefitinib significantly improved objective response rate and quality of life versus docetaxel; progression-free survival, disease control rates, and symptom improvement were similar for the two treatments.
Journal ArticleDOI
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.
Shunsuke Teraoka,Daichi Fujimoto,Takeshi Morimoto,Hayato Kawachi,Munehiro Ito,Yuki Sato,Kazuma Nagata,Atsushi Nakagawa,Kojiro Otsuka,Keiichiro Uehara,Yukihiro Imai,Kaori Ishida,Junya Fukuoka,Keisuke Tomii +13 more
TL;DR: Early irAEs are associated with a better outcome after treatment with immunotherapy after patients with advanced NSCLC who were treated with nivolumab between January and December 2016 were surveyed.
Journal ArticleDOI
Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids.
Yoshihiro Kanemitsu,Hisako Matsumoto,Kenji Izuhara,Yuji Tohda,Hideo Kita,Takahiko Horiguchi,Kazunobu Kuwabara,Keisuke Tomii,Kojiro Otsuka,Masaki Fujimura,Noriyuki Ohkura,Katsuyuki Tomita,Akihito Yokoyama,Hiroshi Ohnishi,Yasutaka Nakano,Tetsuya Oguma,Soichiro Hozawa,Tadao Nagasaki,Isao Ito,Tsuyoshi Oguma,Hideki Inoue,Tomoko Tajiri,Toshiyuki Iwata,Yumi Izuhara,Junya Ono,Shoichiro Ohta,Mayumi Tamari,Tomomitsu Hirota,Tetsuji Yokoyama,Akio Niimi,Akio Niimi,Michiaki Mishima +31 more
TL;DR: In this article, the relationship between serum periostin levels and pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment was determined. But the authors did not identify the specific factors that contribute to the development of airflow limitation.
Journal ArticleDOI
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Akito Hata,Nobuyuki Katakami,Hiroshige Yoshioka,Jumpei Takeshita,Kosuke Tanaka,Shigeki Nanjo,Shiro Fujita,Reiko Kaji,Yukihiro Imai,Kazuya Monden,Takeshi Matsumoto,Kazuma Nagata,Kyoko Otsuka,Ryo Tachikawa,Keisuke Tomii,Kei Kunimasa,Masahiro Iwasaku,Akihiro Nishiyama,Tadashi Ishida,Yoshihiro Nishimura +19 more
TL;DR: The secondary epidermal growth factor receptor (EGFR) mutation Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR‐tyrosine kinase inhibitor (TKI).